Mucorales: Difference between revisions
From IDWiki
m (ββ: oops) |
No edit summary |
||
Line 1: | Line 1: | ||
== |
== Background == |
||
* Order of ubiquitous environmental fungi that are rare causes of aggressive necrotizing infections |
|||
* Ubiquitous environmental fungi often found in decaying organic substances i.e. bread, fruits, vegetables, soil, compose and animal feces. |
|||
* It can infect anyone, but highest prevalence risk factors are: |
|||
** Poorly-controlled diabetes - especially susceptible to the rhinocerebral form |
|||
** Metabolic acidosis, e.g. DKA, which also changes the iron into a form that is more readily absorbed. |
|||
** High-dose steroids/TNF-alpha inhibitors |
|||
** Penetrating trauma/burns |
|||
** Persistent neutropenia |
|||
** Chronic transfusion dependence |
|||
** Chelation therapy with deferoxamine in patients on dialysis, which increases free iron availability. |
|||
** Hemochromatosis - mucorales species require iron in the tissue or bloodstream for invasive growth |
|||
** Malnutrition: can cause necrotizing enterocolitis. |
|||
== |
=== Microbiology === |
||
* Large, aseptate dematiaceous molds with ribbon-like appearance on microscopy |
|||
* Transmission: |
|||
* May or may not have rhizoids, depending on the species |
|||
** Inhalation: from environmental sources (most common) |
|||
* Human pathogens within the order include: |
|||
** Cutaneous routes via trauma or direct injection/inoculation |
|||
** [[Rhizopus species]] |
|||
** Gastrointestinal: from ingestion of spores in immunocompromised patients |
|||
*** [[Rhizopus oryzae]], the most common cause of mucormycosis |
|||
** Injection drug use |
|||
*** [[Rhizopus microsporus]] |
|||
* Immunology |
|||
*** [[Rhizopus stolonifer]] |
|||
** Strong innate immunity and cell-mediated immunity is required and predisposed if prolonged neutropenia |
|||
** [[Mucor species]] |
|||
** To establish infection, spores must overcome killing by phagocytes to germinate into their hyphal forms (the angioinvasive form of the infection). Larger spores may lodge in the nasal turbinates and cause local sinusitis. If you inhale a large spore inoculum, this can lead to a slowly progressing pulmonary mucormycosis even in the immunocompetent host |
|||
*** [[Mucor circinelloides]] |
|||
** Cutaneous mucormycosis occurs secondary to direct inoculation of spores in the context of trauma |
|||
** [[Rhizomucor species]] |
|||
* Invasiveness |
|||
*** [[Rhizomucor pusillus]] |
|||
** Mucorales have an exceptional capacity to invade blood vessels resulting in necrosis of vessel walls and mycotic thrombi. This may lead to infarction and hematogenous dissemination |
|||
** Others |
|||
*** [[Cunninghamella bertholletiae]], which is associated with higher mortality |
|||
*** [[Apophysomyces elegans]] |
|||
*** [[Saksenaea vasiformis]] |
|||
*** [[Absidia corymbifera]] |
|||
*** [[Syncephalastrum racemosum]] |
|||
*** [[Actinomucor elegans]] |
|||
*** [[Cokeromyces recurvatus]] |
|||
*** [[Mortierella wolfii]] |
|||
== |
==== Identification ==== |
||
* ''Rhizopus oryzae'' is the most common cause of invasive disease. |
|||
=== Rhinocerebral mucormycosis === |
|||
* '''Rhinosinusitis''' |
|||
** Present with sinus pain, congestion, headache, mouth or facial pain, hyposmia. Involved tissues are first red, then violaceous then black with thrombosis and tissue necrosis. May see necrotic eschar. |
|||
* '''Rhinocerebral''' |
|||
** The only sign that there has been brain invasion might be bloody nasal discharge. |
|||
** Can present with epidural/subdural abscesses and cavernous and sagittal sinus thrombosis. |
|||
* '''Rhino-orbital''' |
|||
** Usually occurs as a result of invasion from nasal/sinus infection, resulting from ethmoid sinus disease. |
|||
** Patients with extensive disease may present with trigeminal and facial cranial nerve palsies. |
|||
* For diagnosis, ENT scope for tissue biopsy (+/- debridement) is important. |
|||
=== Pulmonary mucormycosis === |
|||
* More common in patients with prolonged neutropenia, solid organ or hematologic transplants. |
|||
* Often occurs concomitantly with sinus infection. |
|||
* Difficult to distinguish from invasive pulmonary aspergillosis and often present with refractory fever despite prolonged broad spectrum antimicrobials, especially if already on anti-mold prophylaxis. |
|||
* Less commonly associated with classic βhalo signβ and may actually see '''βreverse halo signβ''' which is a focal round area of ground-glass attenuation surrounded by ring consolidation. |
|||
=== Skin and soft tissue infection === |
|||
* Usually occur as a result of contaminated trauma. |
|||
* Initially starts with erythema and induration of the skin at the puncture site then progresses to necrosis with a black eschar. It then extend into the deep fascia and muscle layers. |
|||
=== Gastrointestinal mucormycosis === |
|||
* Rare |
|||
* Has been described in malnourished patients and premature infants where it presents as '''necrotizing enterocolitis''' |
|||
* This may lead to peritonitis after invaded through the gastric mucosa and bowel wall |
|||
* Liver abscess have been described after ingestion of herbal products contaminated with mucor |
|||
* Can also be associated with peritoneal dialysis. |
|||
=== Disseminated mucormycosis === |
|||
* Initial source is usually pneumonia |
|||
* Blood cultures/BALs are almost always negative, biopsy is most helpful for diagnosis |
|||
* Diagnosis is almost always made too late |
|||
== Management == |
|||
* '''Surgical Debridement''' |
|||
** Necessary to remove as much of the necrotic tissue as possible |
|||
* '''Antifungals''' |
|||
** Mucorales are inherently resistant to ketoconazole, fluconazole, voriconazole, flucytosine and echinocandins (since no beta-D glucan in cell wall) |
|||
** '''[[Amphotericin B]]''' active (first-line treatment), up to 10 mg/kg if CNS involvement. |
|||
** [[Posaconazole]] active (salvage therapy): |
|||
*** [https://doi.org/10.1007/s11046-014-9792-y 10.1007/s11046-014-9792-y] |
|||
*** Study from 2015 that looked at [[posaconazole]] as salvage therapy. 4/10 patients had proven mucor, 1/10 had IFI of unknown origin. Duration of therapy ranged from 15-355 days, median 47 days. Efficacy of salvage therapy for mucor specifically in this study was 60% |
|||
*** There is a recommendation that for mucormycosis, can consider step down to oral therapy alone with posaconazole after 3 weeks of IV liposomal Amphotericin |
|||
** [[Posaconazole]] as monotherapy: ([https://doi.org/10.1016/j.ijantimicag.2019.01.002 10.1016/j.ijantimicag.2019.01.002]) |
|||
*** Systematic review of contemporary management of mucormycosis infections |
|||
*** [[Posaconazole]] oral suspension monotherapy was prescribed as an initial antifungal in 11 cases. 1/11 died from disseminated infection and there was 1 case of infection recurrence. |
|||
*** The dose used was 800mg po daily of the oral suspension |
|||
*** The [[posaconazole]] MR tablet achieves higher concentrations, but as of yet has only been used for cutaneous infections |
|||
** Synergy: may have some evidence for addition of [[rifampin]] to [[amphotericin]] or [[terbinafine]] and [[amphotericin]]. Also some suggestion regarding use of [[caspofungin]]. |
|||
* '''Hyperbaric oxygen:''' may have benefit in diabetic patients with rhinocerebral disease, but only for the duration of hyperbaric oxygen. |
|||
== Human pathogens == |
|||
* ''Rhizopus oryzae'' |
|||
* ''Rhizopus microsporus'' |
|||
* ''Rhizopus stolonifer'' |
|||
* ''Mucor circinelloides'' |
|||
* ''Rhizomucor pusillus'' |
|||
* ''Cunninghamella bertholletiae'' |
|||
* ''Apophysomyces elegans'' |
|||
* ''Saksenaea vasiformis'' |
|||
* ''Absidia corymbifera'' |
|||
* ''Syncephalastrum racemosum'' |
|||
* ''Actinomucor elegans'' |
|||
* ''Cokeromyces recurvatus'' |
|||
* ''Mortierella wolfii'' |
|||
== Species identification == |
|||
* Microscopy: |
* Microscopy: |
||
Line 111: | Line 33: | ||
{| class="wikitable" |
{| class="wikitable" |
||
! |
!Characteristic |
||
!align="center" |
! align="center" |''Rhizopus'' |
||
!align="center" |
! align="center" |''Mucor'' |
||
!align="center" |
! align="center" |''Rhizomucor'' |
||
!align="center" |
! align="center" |''Absidia'' |
||
|- |
|- |
||
| |
|Growth at 37ΒΊC |
||
|align="center"| +(β) |
| align="center" | +(β) |
||
|align="center" |
| align="center" |β(+) |
||
|align="center"| + |
| align="center" | + |
||
|align="center"| + |
| align="center" | + |
||
|- |
|- |
||
| |
|Growth at 54ΒΊC |
||
|align="center" |
| align="center" |β |
||
|align="center" |
| align="center" |β |
||
|align="center"| + |
| align="center" | + |
||
|align="center" |
| align="center" |β |
||
|- |
|- |
||
| |
|Sporangium |
||
|align="center" |
| align="center" |Globose |
||
|align="center" |
| align="center" |Globose |
||
|align="center" |
| align="center" |Globose |
||
|align="center"| |
| align="center" | |
||
|- |
|- |
||
| |
|Rhizoids |
||
|align="center" |
| align="center" |Well-developer |
||
|align="center" |
| align="center" |Absent |
||
|align="center" |
| align="center" |Primitive |
||
|align="center" |
| align="center" |Present but inconspicuous |
||
|- |
|- |
||
| |
|Apophysis |
||
|align="center" |
| align="center" |Inconspicuous |
||
|align="center" |
| align="center" |Absent |
||
|align="center" |
| align="center" |Absent |
||
|align="center" |
| align="center" |Present |
||
|- |
|- |
||
| |
|Growth on cycloheximide |
||
|align="center" |
| align="center" |β(+) |
||
|align="center"| +(β) |
| align="center" | +(β) |
||
|align="center" |
| align="center" |β |
||
|align="center"| +(β) |
| align="center" | +(β) |
||
|} |
|} |
||
===Epidemiology=== |
|||
*Ubiquitous environmental fungi often found in decaying organic substances i.e. bread, fruits, vegetables, soil, compose and animal feces. |
|||
*It can infect anyone, but highest prevalence risk factors are: |
|||
**Poorly-controlled diabetes - especially susceptible to the rhinocerebral form |
|||
**Metabolic acidosis, e.g. DKA, which also changes the iron into a form that is more readily absorbed. |
|||
**High-dose steroids/TNF-alpha inhibitors |
|||
**Penetrating trauma/burns |
|||
**Persistent neutropenia |
|||
**Chronic transfusion dependence |
|||
**Chelation therapy with deferoxamine in patients on dialysis, which increases free iron availability. |
|||
**Hemochromatosis - mucorales species require iron in the tissue or bloodstream for invasive growth |
|||
**Malnutrition: can cause necrotizing enterocolitis. |
|||
===Pathogenesis=== |
|||
*Transmission: |
|||
**Inhalation: from environmental sources (most common) |
|||
**Cutaneous routes via trauma or direct injection/inoculation (most common in immunocompetent hosts) |
|||
**Gastrointestinal: from ingestion of spores in immunocompromised patients |
|||
**Injection drug use |
|||
*Immunology |
|||
**Strong innate immunity and cell-mediated immunity is required and predisposed if prolonged neutropenia |
|||
**To establish infection, spores must overcome killing by phagocytes to germinate into their hyphal forms (the angioinvasive form of the infection). Larger spores may lodge in the nasal turbinates and cause local sinusitis. If you inhale a large spore inoculum, this can lead to a slowly progressing pulmonary mucormycosis even in the immunocompetent host |
|||
**Cutaneous mucormycosis occurs secondary to direct inoculation of spores in the context of trauma |
|||
*Invasiveness |
|||
**Mucorales have an exceptional capacity to invade blood vessels resulting in necrosis of vessel walls and mycotic thrombi. This may lead to infarction and hematogenous dissemination |
|||
==Clinical Manifestations== |
|||
===Rhinocerebral Mucormycosis=== |
|||
*'''Rhinosinusitis''' |
|||
**Present with sinus pain, congestion, headache, mouth or facial pain, hyposmia. Involved tissues are first red, then violaceous then black with thrombosis and tissue necrosis. May see necrotic eschar. |
|||
*'''Rhinocerebral''' |
|||
**The only sign that there has been brain invasion might be bloody nasal discharge. |
|||
**Can present with epidural/subdural abscesses and cavernous and sagittal sinus thrombosis. |
|||
*'''Rhino-orbital''' |
|||
**Usually occurs as a result of invasion from nasal/sinus infection, resulting from ethmoid sinus disease. |
|||
**Patients with extensive disease may present with trigeminal and facial cranial nerve palsies. |
|||
*For diagnosis, ENT scope for tissue biopsy (+/- debridement) is important. |
|||
=== |
===Pulmonary Mucormycosis=== |
||
*More common in patients with prolonged neutropenia, solid organ or hematologic transplants. |
|||
* Clinical: |
|||
*Often occurs concomitantly with sinus infection. |
|||
** Most common agent of mucormycosis |
|||
*Difficult to distinguish from invasive pulmonary aspergillosis and often present with refractory fever despite prolonged broad spectrum antimicrobials, especially if already on anti-mold prophylaxis. |
|||
** Rapidly progressing infection characterized by tissue necrosis and products of infarcts in the brain, the lungs and the intestines. Patients with DKA, Malnutrition, severe burns or immunocompromising conditions are at highest risk |
|||
*Less commonly associated with classic βhalo signβ and may actually see '''βreverse halo signβ''' which is a focal round area of ground-glass attenuation surrounded by ring consolidation. |
|||
* Macroscopic: |
|||
** Very rapid growth |
|||
** Texture deeply cottony |
|||
** Colour white becoming grey brown on the surface, reverse pale |
|||
* Microscopic: |
|||
** Broad hyphae, scarcely septate |
|||
** Brown sporangiophores which may be simple, branched. |
|||
** They can arise singly or in a group/cluster on the stolons called rhizoids, |
|||
** Round sporangia |
|||
* Temperature: |
|||
** Usually grows at 37ΒΊC |
|||
** DOES NOT grow at 54ΒΊC |
|||
===Skin and Soft Tissue infection=== |
|||
=== ''Mucor'' === |
|||
*Usually occur as a result of contaminated trauma. |
|||
* Clinical: |
|||
*Initially starts with erythema and induration of the skin at the puncture site then progresses to necrosis with a black eschar. It then extend into the deep fascia and muscle layers. |
|||
** Less commonly causes mucormycosis, usually in the severely ill. |
|||
* Macroscopic: |
|||
** Very rapid growth |
|||
** Wooly texture |
|||
** Greyish-brown colour on the surface, reverse pale |
|||
* Microscopic: |
|||
** Broad hyphae, scarcely septate |
|||
** Branched sporangiophores |
|||
** Sporangia with columellas |
|||
** No apophysis (funnel-shaped swelling) |
|||
** Sporangiospores round to ellipsoidal |
|||
** Chlamydospores present |
|||
** Rhizoids/stolons absent |
|||
* Temperature: |
|||
** Grows at 37ΒΊC |
|||
** DOES NOT grow at 54ΒΊC |
|||
===Gastrointestinal Mucormycosis=== |
|||
=== ''Rhizomucor'' === |
|||
*Rare |
|||
* Clinical: |
|||
*Has been described in malnourished patients and premature infants where it presents as '''necrotizing enterocolitis''' |
|||
** Occasionally an agent of pulmonary, rhinofacial, cerebral or disseminated mucormycosis. Usually seen in hematological malignancies |
|||
*This may lead to peritonitis after invaded through the gastric mucosa and bowel wall |
|||
* Macroscopic: |
|||
*Liver abscess have been described after ingestion of herbal products contaminated with mucor |
|||
** Rapid growth |
|||
*Can also be associated with peritoneal dialysis. |
|||
** Wooly texture |
|||
** Pale brown on the surface, reverse white |
|||
* Microscopic: |
|||
** Broad hyphae, scarcely septate |
|||
** Rudimentary rhizoids and stolons but RARE |
|||
** Branched sporangiophores |
|||
** Apophysis absent |
|||
** Sporangiospores round or oval |
|||
* Temperature: |
|||
** '''Grows at 54ΒΊC''' which is a unique feature and allows it to be identified |
|||
===Disseminated Mucormycosis=== |
|||
=== ''Lictheimia'' (previously ''Absidia'') === |
|||
*Initial source is usually pneumonia |
|||
* Clinical: |
|||
*Blood cultures/BALs are almost always negative, biopsy is most helpful for diagnosis |
|||
** Most commonly implicated in opportunistic pulmonary invasions, infections of the skin, the meninges and kidneys. Usually in the immunocompromised host. |
|||
*Diagnosis is almost always made too late |
|||
** Also causes mycotic abortion in cows |
|||
* Macroscopic: |
|||
** Rapid growth |
|||
** Wooly texture |
|||
** White to grayish-brown on surface, clear reverse |
|||
* Microscopic: |
|||
** Broad hyphae, aseptate |
|||
** Branched Sporangiophores with APOPHYSIS (funnel-shaped swelling) beneath the sporangium |
|||
** Few rhizoids |
|||
* Temperature: |
|||
** Grows more rapidly at 37ΒΊC compared to 25ΒΊC |
|||
** ''L. corymbifera'' (the only human pathogen) is able to grow up to 52ΒΊC but no growth at 54ΒΊC |
|||
=== |
=== Prognosis and Complications === |
||
* Overall mortality ranges from 40 to 80% depending on underlying risk factors, but is even higher in disseminated or CNS disease |
|||
* Clinical: |
|||
** Causes mucormycosis. Often via trauma involving inoculation of soil or vegetative matter. |
|||
** Host is usually IMMUNOCOMPETENT. |
|||
** Most commonly presents as necrotizing fasciitis, osteomyelitis and angioinvasion |
|||
* Macroscopic: |
|||
** Similar in appearance to ''L.corymbifera'' but has white colonies |
|||
** Fluffy and cottony |
|||
** Does not sporulate on routine media |
|||
* Microscopic: |
|||
** Bell-shaped apophysis |
|||
** Foot-cell like hyphal segment |
|||
** Rhizoids |
|||
* Temperature: |
|||
** Grows at 37ΒΊC |
|||
** Grows rapidly at 42ΒΊC and up to 50ΒΊC |
|||
== Investigations == |
|||
=== ''Cunninghamella bertholletiae'' === |
|||
* For pulmonary disease, a CT chest can show: |
|||
* Clinical: |
|||
** Halo sign: a nodular infiltrate surrounded by a ring of ground glass, representing ischemia and angioinvasive disease |
|||
** Occasionally can cause pulmonary or disseminated mucormycosis in a severely ill patient |
|||
** Reversed halo signs: an area of ground glass surrounded by a ring of consolidation |
|||
** Angioinvasive |
|||
** Vascular occlusion sign: termination of a vessel at the edge of a focal lesion, seen on CTPA |
|||
** Sited to have the '''worst prognosis''' of all the mucorales |
|||
* For suspected rhinocerebral disease, a CT or MRI, with MRI preferred for eye or brain involvement |
|||
* Macroscopic: |
|||
** Very rapid growth |
|||
** Cottony texture |
|||
** White to grey on surface, reverse pale |
|||
* Microscopic: |
|||
** Broad hyphae, aseptate |
|||
** Branched sporangiophores terminating in a vesicle |
|||
** One spored sponrangioles formed on the denticles of the vesicle surface |
|||
* Temperature: |
|||
** Non-pathogenic forms will grow at 40ΒΊC |
|||
==Management== |
|||
== Basidiobolus and Conidiobolus == |
|||
*'''Surgical Debridement''' |
|||
* Refer to '''[[entomophthoromycosis]]''' |
|||
**Necessary to remove as much of the necrotic tissue as possible |
|||
*'''Antifungals''' |
|||
**Mucorales are inherently resistant to ketoconazole, fluconazole, voriconazole, flucytosine and echinocandins (since no beta-D glucan in cell wall) |
|||
**'''First-line:''' [[Amphotericin B|liposomal amphotericin B]] 5 to 10 mg/kg daily |
|||
***Liposomal preferred to deoxycholate |
|||
***Use higher end of dose range for CNS involvement or solid-organ transplant |
|||
***Dose-reduce if renal toxicity, but ideally stay above 5 mg/kg |
|||
**'''Alternatives''' that can be used as first-line or as salvage: |
|||
***[[Isavuconazole]] 200 mg IV q8h for 6 doses followed by 200 mg IV daily |
|||
***[[Posaconazole]] 300 mg IV/PO q12h for 2 doses followed by 300 mg IV/PO daily |
|||
**Synergy: may have some evidence for addition of [[rifampin]] to [[amphotericin]] or [[terbinafine]] and [[amphotericin]]. Also some suggestion regarding use of [[caspofungin]]. |
|||
**Can step down to oral [[isavuconazole]] or [[posaconazole]] if improving on repeat imaging |
|||
**Duration is until immunosuppression is reversed and complete radiographical resolution of the infection |
|||
*'''Hyperbaric oxygen:''' may have benefit in diabetic patients with rhinocerebral disease, but only for the duration of hyperbaric oxygen. |
|||
[[Category:Microbiology]] |
[[Category:Microbiology]] |
||
[[Category: |
[[Category:Dematiaceous molds]] |
Revision as of 01:32, 26 August 2020
Background
- Order of ubiquitous environmental fungi that are rare causes of aggressive necrotizing infections
Microbiology
- Large, aseptate dematiaceous molds with ribbon-like appearance on microscopy
- May or may not have rhizoids, depending on the species
- Human pathogens within the order include:
- Rhizopus species
- Rhizopus oryzae, the most common cause of mucormycosis
- Rhizopus microsporus
- Rhizopus stolonifer
- Mucor species
- Rhizomucor species
- Others
- Cunninghamella bertholletiae, which is associated with higher mortality
- Apophysomyces elegans
- Saksenaea vasiformis
- Absidia corymbifera
- Syncephalastrum racemosum
- Actinomucor elegans
- Cokeromyces recurvatus
- Mortierella wolfii
- Rhizopus species
Identification
- Microscopy:
- Sporangia on an apophysis on a sporangiophore that comes off of a stolon. May have rhizoids at base.
- Sporangia may be globose (round) or pyriform (teardrop-shaped), may have collarettes.
Characteristic | Rhizopus | Mucor | Rhizomucor | Absidia |
---|---|---|---|---|
Growth at 37ΒΊC | +(β) | β(+) | + | + |
Growth at 54ΒΊC | β | β | + | β |
Sporangium | Globose | Globose | Globose | |
Rhizoids | Well-developer | Absent | Primitive | Present but inconspicuous |
Apophysis | Inconspicuous | Absent | Absent | Present |
Growth on cycloheximide | β(+) | +(β) | β | +(β) |
Epidemiology
- Ubiquitous environmental fungi often found in decaying organic substances i.e. bread, fruits, vegetables, soil, compose and animal feces.
- It can infect anyone, but highest prevalence risk factors are:
- Poorly-controlled diabetes - especially susceptible to the rhinocerebral form
- Metabolic acidosis, e.g. DKA, which also changes the iron into a form that is more readily absorbed.
- High-dose steroids/TNF-alpha inhibitors
- Penetrating trauma/burns
- Persistent neutropenia
- Chronic transfusion dependence
- Chelation therapy with deferoxamine in patients on dialysis, which increases free iron availability.
- Hemochromatosis - mucorales species require iron in the tissue or bloodstream for invasive growth
- Malnutrition: can cause necrotizing enterocolitis.
Pathogenesis
- Transmission:
- Inhalation: from environmental sources (most common)
- Cutaneous routes via trauma or direct injection/inoculation (most common in immunocompetent hosts)
- Gastrointestinal: from ingestion of spores in immunocompromised patients
- Injection drug use
- Immunology
- Strong innate immunity and cell-mediated immunity is required and predisposed if prolonged neutropenia
- To establish infection, spores must overcome killing by phagocytes to germinate into their hyphal forms (the angioinvasive form of the infection). Larger spores may lodge in the nasal turbinates and cause local sinusitis. If you inhale a large spore inoculum, this can lead to a slowly progressing pulmonary mucormycosis even in the immunocompetent host
- Cutaneous mucormycosis occurs secondary to direct inoculation of spores in the context of trauma
- Invasiveness
- Mucorales have an exceptional capacity to invade blood vessels resulting in necrosis of vessel walls and mycotic thrombi. This may lead to infarction and hematogenous dissemination
Clinical Manifestations
Rhinocerebral Mucormycosis
- Rhinosinusitis
- Present with sinus pain, congestion, headache, mouth or facial pain, hyposmia. Involved tissues are first red, then violaceous then black with thrombosis and tissue necrosis. May see necrotic eschar.
- Rhinocerebral
- The only sign that there has been brain invasion might be bloody nasal discharge.
- Can present with epidural/subdural abscesses and cavernous and sagittal sinus thrombosis.
- Rhino-orbital
- Usually occurs as a result of invasion from nasal/sinus infection, resulting from ethmoid sinus disease.
- Patients with extensive disease may present with trigeminal and facial cranial nerve palsies.
- For diagnosis, ENT scope for tissue biopsy (+/- debridement) is important.
Pulmonary Mucormycosis
- More common in patients with prolonged neutropenia, solid organ or hematologic transplants.
- Often occurs concomitantly with sinus infection.
- Difficult to distinguish from invasive pulmonary aspergillosis and often present with refractory fever despite prolonged broad spectrum antimicrobials, especially if already on anti-mold prophylaxis.
- Less commonly associated with classic βhalo signβ and may actually see βreverse halo signβ which is a focal round area of ground-glass attenuation surrounded by ring consolidation.
Skin and Soft Tissue infection
- Usually occur as a result of contaminated trauma.
- Initially starts with erythema and induration of the skin at the puncture site then progresses to necrosis with a black eschar. It then extend into the deep fascia and muscle layers.
Gastrointestinal Mucormycosis
- Rare
- Has been described in malnourished patients and premature infants where it presents as necrotizing enterocolitis
- This may lead to peritonitis after invaded through the gastric mucosa and bowel wall
- Liver abscess have been described after ingestion of herbal products contaminated with mucor
- Can also be associated with peritoneal dialysis.
Disseminated Mucormycosis
- Initial source is usually pneumonia
- Blood cultures/BALs are almost always negative, biopsy is most helpful for diagnosis
- Diagnosis is almost always made too late
Prognosis and Complications
- Overall mortality ranges from 40 to 80% depending on underlying risk factors, but is even higher in disseminated or CNS disease
Investigations
- For pulmonary disease, a CT chest can show:
- Halo sign: a nodular infiltrate surrounded by a ring of ground glass, representing ischemia and angioinvasive disease
- Reversed halo signs: an area of ground glass surrounded by a ring of consolidation
- Vascular occlusion sign: termination of a vessel at the edge of a focal lesion, seen on CTPA
- For suspected rhinocerebral disease, a CT or MRI, with MRI preferred for eye or brain involvement
Management
- Surgical Debridement
- Necessary to remove as much of the necrotic tissue as possible
- Antifungals
- Mucorales are inherently resistant to ketoconazole, fluconazole, voriconazole, flucytosine and echinocandins (since no beta-D glucan in cell wall)
- First-line: liposomal amphotericin B 5 to 10 mg/kg daily
- Liposomal preferred to deoxycholate
- Use higher end of dose range for CNS involvement or solid-organ transplant
- Dose-reduce if renal toxicity, but ideally stay above 5 mg/kg
- Alternatives that can be used as first-line or as salvage:
- Isavuconazole 200 mg IV q8h for 6 doses followed by 200 mg IV daily
- Posaconazole 300 mg IV/PO q12h for 2 doses followed by 300 mg IV/PO daily
- Synergy: may have some evidence for addition of rifampin to amphotericin or terbinafine and amphotericin. Also some suggestion regarding use of caspofungin.
- Can step down to oral isavuconazole or posaconazole if improving on repeat imaging
- Duration is until immunosuppression is reversed and complete radiographical resolution of the infection
- Hyperbaric oxygen: may have benefit in diabetic patients with rhinocerebral disease, but only for the duration of hyperbaric oxygen.